The Alliance says that the report claimed that gaps in legal authority and insufficient resources hindered the FDA's efforts to better understand and manage the potential risks from hundreds of new products incorporating nanotechnologies.

"The NanoBusiness Alliance believes that the FDA has robust legal authority and significant discretion in setting the protocols for testing to regulate nanotechnologies," said Sean Murdock, executive director of the alliance. "As the technology matures, new tests will be available and will be required or recommended for use, as appropriate."

The FDA held a public meeting on FDA-regulated products containing nanotechnology materials on 10 October.